Reports
Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global cardiovascular drugs market is expected to grow at a CAGR of about 1.5% in the forecast period of 2022-2027.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America dominates the global cardiovascular drugs industry, owing to the increased awareness about various heart diseases within the region. The United States represent the most important marketplace for cardiovascular drugs followed by Canada in North America. On the other hand, Asia Pacific is predicted to witness high growth rates in the coming years, thanks to many companies constructing their R&D facilities in the region. Less stringent wages and availability of skilled labour attracts manufacturing companies which is further boosting the growth in the Asia Pacific region.
Additionally, increasing awareness about heart related problems is supporting within the growth of cardiovascular drugs market within the region. China, India, and Japan are expected to be the fastest growing cardiovascular drugs markets thanks to rising cases of heart diseases and extensive pipeline drugs. Increasing ageing population and rising number of lifestyle diseases are also contributing to the growth of global cardiovascular drugs industry.
Cardiovascular drugs refer to agents used for the treatment of diseases related to the cardiovascular system, which include blood clots, stroke, arteria coronaria disease, variation in vital sign, arrhythmias, high cholesterol, and coronary failure.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cardiovascular drugs can be divided on the basis of drug type into:
On the basis of disease indication, cardiovascular drugs can be divided into:
Cardiovascular drugs can be segmented on the basis of distribution channel into:
The regional markets for global cardiovascular drugs industry can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cardiovascular drugs are extremely helpful in treating various heart related dysfunction. The rising prevalence of heart stroke and cardiovascular diseases is one among the key reasons for the expansion of the cardiovascular drugs market. Cardiovascular diseases have shown stable increase in prevalence worldwide, driven by numerous modern lifestyle changes. Factors like sedentary lifestyle, excess consumption of alcohol, stress, unhealthy eating habits, smoking are all factors liable for the rise within the number of cardiovascular disorders among the young population. A number of the opposite crucial drivers for global cardiovascular drugs industry growth is that the increased awareness regarding cardiovascular health and therefore the corresponding increase in product launches. The rising number of diabetic patients holds immense potential to the expansion of worldwide cardiovascular drugs industry.
The report gives a detailed analysis of the following key players in the global cardiovascular drugs industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2020 |
Historical Period | 2017-2021 |
Forecast Period | 2022-2027 |
Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Type, Disease Indication, Distribution Channel, Region |
Breakup by Drug Type | Antihypertensive, Antihyperlipidemic, Anticoagulants, Antiarrhythmics, Others |
Breakup by Disease Indication | Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, Others |
Breakup by Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online, Others |
Breakup by Region | North America, Latin America, Europe, Middle East and Africa, Asia Pacific |
Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
Companies Covered | Baxter International Inc., Pfizer Inc., Bayer AG, Johnson & Johnson Services, Inc., Novartis AG, Boehringer Ingelheim International GmbH, Others |
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Cardiovascular Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Cardiovascular Drugs Historical Market (2017-2021)
8.3 Global Cardiovascular Drugs Market Forecast (2022-2027)
8.4 Global Cardiovascular Drugs Market by Drug Type
8.4.1 Antihypertensive
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Antihyperlipidemic
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Anticoagulants
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Antiarrhythmics
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2017-2021)
8.4.4.3 Forecast Trend (2022-2027)
8.4.5 Others
8.5 Global Cardiovascular Drugs Market by Disease Indication
8.5.1 Hypertension
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Hyperlipidemia
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Coronary Artery Disease
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.5.4 Arrhythmia
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2017-2021)
8.5.4.3 Forecast Trend (2022-2027)
8.5.5 Others
8.6 Global Cardiovascular Drugs Market by Distribution Channel
8.6.1 Hospital Pharmacies
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Retail Pharmacies
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Online
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2017-2021)
8.6.3.3 Forecast Trend (2022-2027)
8.6.4 Others
8.7 Global Cardiovascular Drugs Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Baxter International Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Pfizer Inc.
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Bayer AG
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Johnson & Johnson Services, Inc.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Novartis AG
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Boehringer Ingelheim International GmbH
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Cardiovascular Drugs Market: Key Industry Highlights, 2016 and 2026
2. Global Cardiovascular Drugs Historical Market: Breakup by Drug Type (USD Billion), 2017-2021
3. Global Cardiovascular Drugs Market Forecast: Breakup by Drug Type (USD Billion), 2022-2027
4. Global Cardiovascular Drugs Historical Market: Breakup by Disease Indication (USD Billion), 2017-2021
5. Global Cardiovascular Drugs Market Forecast: Breakup by Disease Indication (USD Billion), 2022-2027
6. Global Cardiovascular Drugs Historical Market: Breakup by Distribution Channel (USD Billion), 2017-2021
7. Global Cardiovascular Drugs Market Forecast: Breakup by Distribution Channel (USD Billion), 2022-2027
8. Global Cardiovascular Drugs Historical Market: Breakup by Region (USD Billion), 2017-2021
9. Global Cardiovascular Drugs Market Forecast: Breakup by Region (USD Billion), 2022-2027
10. North America Cardiovascular Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
11. North America Cardiovascular Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
12. Europe Cardiovascular Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
13. Europe Cardiovascular Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Asia Pacific Cardiovascular Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Asia Pacific Cardiovascular Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Latin America Cardiovascular Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Latin America Cardiovascular Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Middle East and Africa Cardiovascular Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
19. Middle East and Africa Cardiovascular Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
20. Global Cardiovascular Drugs Market Structure
The global cardiovascular drugs market is projected to grow at a CAGR of 1.5% between 2022 and 2027.
The major drivers of the market include the sedentary lifestyle, excess consumption of alcohol, stress and smoking, increased awareness regarding cardiovascular health, unhealthy eating habits, increasing ageing population, and rising number of lifestyle diseases.
The rising prevalence of heart stroke and cardiovascular diseases and the rising number of diabetic patients are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Cardiovascular drugs can be divided on the basis of drug type into antihypertensive, antihyperlipidemic, anticoagulants, and antiarrhythmics, among others.
Based on disease indication, cardiovascular drugs can be divided into hypertension, hyperlipidemia, coronary artery disease, and arrhythmia, among others.
The distribution channels include hospital pharmacies, retail pharmacies, and online, among others.
The major players in the industry are Baxter International Inc., Pfizer Inc., Bayer AG, Johnson & Johnson Services, Inc., Novartis AG, and Boehringer Ingelheim International GmbH, among others.
The global cardiovascular drugs market was driven by the rising prevalence of heart stroke and cardiovascular diseases in the historical period. Aided by the increasing ageing population and rising number of diabetic patients, the market is expected to witness further growth in the forecast period of 2022-2027, growing at a CAGR of 1.5%.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Cardiovascular drugs can be divided on the basis of drug type into antihypertensive, antihyperlipidemic, anticoagulants, and antiarrhythmics, among others. Based on disease indication, cardiovascular drugs can be divided into hypertension, hyperlipidemia, coronary artery disease, and arrhythmia, among others. The distribution channels include hospital pharmacies, retail pharmacies, and online, among others. The major regional markets for the cardiovascular drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The major players in the industry are Baxter International Inc., Pfizer Inc., Bayer AG, Johnson & Johnson Services, Inc., Novartis AG, and Boehringer Ingelheim International GmbH, among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.